Table 1. Baseline demographic characteristics and echocardiography parameters of all patients
Patient
(No.)
|
Sex
|
Age
(years)
|
WHO FC
|
6MWD
(m)
|
LVEF
(%)
|
RV diameter
(mm)
|
PASP
(mmHg)
|
1
|
M
|
29
|
Ⅲ
|
440
|
53
|
69*42
|
115
|
2
|
F
|
19
|
Ⅱ
|
400
|
67
|
57*29
|
120
|
3
|
F
|
32
|
Ⅱ-Ⅲ
|
170
|
72
|
68*40
|
144
|
4
|
F
|
34
|
Ⅲ
|
450
|
67
|
75*35
|
104
|
Abbreviation: WHO FC, WHO functional class; 6MWD, six-minute walking distances; PASP, pulmonary artery systolic pressure; LVEF, left ventricular ejection fraction; RV, right ventricle.
Table 2. Baseline hemodynamics parameters measured by right heart catheterization
Patient
(No.)
|
RAP
(mm Hg)
|
PASP
(mm Hg)
|
TPR
(Wood U)
|
PVR
(Wood U)
|
SVR
(Wood U)
|
PVR/SVR
|
AOP
(mmHg)
|
SaO2(%)
|
Qp/Qs
|
|
|
|
|
|
|
|
|
|
Baseline
|
O2 test
|
1
|
13/6/9
|
105/73/81
|
18.95
|
16.14
|
28.29
|
0.57
|
114/69/79
|
91.8
|
1.73
|
2.92
|
2
|
5/0/2
|
105/65/85
|
15.82
|
14.70
|
40.34
|
0.36
|
115/65/80
|
95
|
2.13
|
2.46
|
3
|
9/2/5
|
143/63/95
|
40.31
|
36.91
|
36.07
|
1.02
|
142/62/95
|
88.9
|
1.00
|
1.72
|
4
|
11/3/7
|
134/72/98
|
23.13
|
21.01
|
24.50
|
0.86
|
130/70/90
|
89.7
|
1.10
|
2.60
|
Abbreviation: RAP, right atrium pressure; PASP, pulmonary artery systolic pressure; TPR, total pulmonary resistance; PVR, pulmonary vascular resistance. Qp/Qs, pulmonary-systemic blood flow ratio; SVR, systemic vascular resistance; AOP, aortic pressure; SaO2, systemic arterial oxygen saturation.
Table 3. Initial and adjusted PAH-targeted drugs before TCC
Paitent (No.)
|
intial
|
adjusted
|
1
|
vardenafil 5mg bid
|
vardenafil 5mg bid
bosentan 125mg bid
|
2
|
tadanafil 20mg qd
|
tadalafil 20mg qd
bosentan 125mg bid
|
3
|
bosentan 125mg bid
tadanafil 20mg qd
|
bosentan 125mg bid
tadanafil 20mg qd
|
4
|
ambrisentan 5mg qd
tadalafil 20mg qd
|
ambrisentan 5mg qd
tadalafil 20mg qd
|
Table 4. Comparisons between pre-occlusion and post-occlusion parameters
Patient (No.)
|
PDA diameter
(mm)
|
PASP
(mmHg)
|
|
AOP
(mmHg)
|
|
SaO2
(%)
|
|
|
Before occlusion
|
After occlusion
|
|
Before occlusion
|
After occlusion
|
|
Before occlusion
|
After occlusion
|
1
2
3
4
|
10
9
9
11
|
105
116
138
145
|
66
68
74
72
|
113
122
137
144
|
124
127
150
153
|
96
97
92.3
97.2
|
98
100
100
100
|
Abbreviation: PDA, patent ductus arteriosus; PASP, pulmonary artery systolic pressure; AOP, aorta pressure; SaO2, systemic arterial oxygen saturation.
Table 5. PASP changes during follow up by echocardiography
Patient (No.)
|
PASP
(mmHg)
|
|
|
12m
|
24m
|
36m
|
48m
|
60m
|
72m
|
1
|
31
|
28
|
27
|
/
|
/
|
/
|
2
|
58
|
57
|
55
|
53
|
72
|
58
|
3
|
98
|
140
|
140
|
111
|
/
|
/
|
4
|
70
|
87
|
131
|
/
|
/
|
/
|
Abbreviation: PASP, pulmonary artery systolic pressure.
Table 6. Hemodynamics parameters measured by right heart catheterization at follow-up
Paitent (No.)
|
RAP
(mmHg)
|
PASP
(mmHg)
|
CO
(L/min)
|
SaO2(%)
|
PVR
(Wood U)
|
SVR
(Wood U)
|
PVR/SVR
|
2
|
11/6/9
|
55/18/36
|
6.0
|
98
|
3.83
|
13.33
|
0.29
|
3
|
15/8/11
|
139/47/82
|
5.6
|
94.3
|
12.68
|
14.29
|
0.88
|
4
|
12/1/6
|
136/54/86
|
5.9
|
92.2
|
12.54
|
15.67
|
0.80
|
Abbreviations: RAP, right atrium pressure; PASP, pulmonary artery systolic pressure; CO, cardiac output; SaO2, systemic arterial oxygen saturation; PVR, pulmonary vascular resistance; SVR, systemic vascular resistance.
Table 7.RV diameter, WHO FC ,6MWD and PAH-targeted drugs at the last follow-up
Paitent
(No.)
|
RV diameter(mm)
|
WHO FC
|
6MWD
(m)
|
PAH-targeted
drugs
|
1
|
50*25
|
Ⅰ
|
550
|
/
|
2
|
55*28
|
Ⅰ
|
500
|
ambrisentan
|
3
|
65*40
|
Ⅱ
|
440
|
bosentan,sildenafil
|
4
|
59*39
|
Ⅱ
|
490
|
macitentan,tadalafil
|
Abbreviations: RV, right ventricle; WHO FC, WHO functional class; 6MWD, six-minute walking distances.